RISK-ASSOCIATED THERAPY OF MUSCULAR-NONINVASIVE BLADDER CANCER


Cite item

Full Text

Abstract

Intravesicular chemotherapy (IVCT) and BCG-therapy are the most effective methods for preventing disease relapse and progression in patients with intermediate and high risk muscular-noninvasive bladder cancer. Prospective trend of adjuvant use of IVCT and BCG-therapy is a combination of these methods with various physical factors (photodynamic therapy, electrodiffusion, microwave hyperthermia).

References

  1. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2009. М., 2010.
  2. Чиссов В.И., Старинский В.В., Петрова Г.В.. Злокачественны новообразования в России в 2009 году. Заболеваемость и смертность. М., 2011.
  3. EAU Guidelines, 2011.
  4. Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56(3):430-42.
  5. Botteman MF, Pashos CL, Hauser RS, et al. Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res 2003;12(6):675-88.
  6. Millan-Rodríguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164(3):680-84.
  7. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90.
  8. Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009;55(4):773-80.
  9. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol 2004;56(1):65-72.
  10. Volpe A, Racioppi M, D'Agostino D, et al. Mitomycin C for the treatment of bladder cancer. Minerva Urol Nefrol 2010;62(2):133-44.
  11. Van der Meijden APM, Bohle A, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005;48(3):363-71.
  12. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53(4):709-19.
  13. Sarosdy MF. Principles of intravesical chemotherapy and immunotherapy. Urol Clin North Am 1992;19(3):509-19.
  14. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of EORTC, and MRC randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996;156(6):1934-40.
  15. Giesbers AA, Van Helsdingen PJ, Kramer AE. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. Br J Urol 1989;63(2):176-79.
  16. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003;170(3):777-82.
  17. Van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46(1):65-71.
  18. Solsona E, Gonzalez M, Fernandez JM, et al. Random trial comparing intravesical chemoinduction with MMC to BCG vs. intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Eur Urol 2002;40(1):394.
  19. Lottner C, Knuechel R, Bernhardt G, et al. Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates. Cancer Lett 2004;203(2):171-80.
  20. French AJ, Datta SN, Allman R, et al. Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. BJU Int 2004;93(1):156-61.
  21. Skyrme RJ, French AJ, Datta SN, et al. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BJU Int 2005;95(9):1206-10.
  22. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604.
  23. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-86.
  24. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. In Lamm DL, ed. The Urologic Clinics of North America, Philadelphia, PA: W.B. Saunders Co. 1992;19:573-80.
  25. Nadler RB, Catalona WJ, Hudson MA, et al. Durability of tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 1994;152(2):367-73.
  26. Melekos MD, Chionis H, Pantazakos A, et al. Intravesical Bacillus Calmette-Guerin Immunoprophylaxis Of Superficial Bladder Cancer: Results Of A Controlled Prospective Trial With Modified Treatment Schedule. J Urol 1993;149:744.
  27. Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin versus transurethral resection plus Bacillus Calmette-Guerin. J Urol 1996;156:962-66.
  28. Smaldone MC, Gayed BA, Tomaszewski JJ. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva 2009;61(2):71-89.
  29. Martinez-Pineiro JA, Leon JJ, Martinez-Pineiro L Jr, et al. Bacillus Calmette-Guerin versus Doxorubicin versus Thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer. Journal of Urology 1990;143:502-06.
  30. Jauhianen K, Rintala E, Alfthan O. Immunotherapy versus chemotherapy in intravesical treatment of superficial urinary bladder cancer. Immunotherapy of Urological Tumors, Edinburgh: Churchill Livingston 1990:13-60.
  31. Lamm DL, Crawford ED, Blumenstein B, et al. SWOG 8795: A randomized comparison of bacillus Calmette-Guerin and mitomycin-C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. Urol Oncol 1995;1:119-26.
  32. Duchek M, Johansson R, Jahnson S, et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57(1):25-31.
  33. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57(5):766-73.
  34. Jarvinen R, Kaasinen E, Sankila A, et al. Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56(2):260-65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies